(Approval lapsed) CELESTONE SOLUSPAN (betamethasone sodium phosphate and betamethasone acetate) Injectable 30mg/5mL Suspension, USP (USA)

It is indicated in the treatment of both severe and moderate conditions, in acute and chronic self-limiting diseases responsive to systemic corticosteroid therapy, especially in patients for whom treatment with oral corticosteroid medication is not feasible.

Representative conditions:

• Rheumatic disorders: Rheumatoid arthritis, acute and subacute bursitis, epicondylitis, acute non-specific tenosynovitis, myositis, tendinitis, psoriatic arthritis.
• Collagen diseases: Systemic lupus erythematosus, dermatomyositis.
• Allergic states: Status asthmaticus, chronic bronchial asthma, seasonal or perennial allergic rhinitis, contact dermatitis, atopic dermatitis, hypersensitivity reactions to drug.
• Dermatological conditions: Localised, hypertrophic, infiltrated lesions of lichen planus, psoriatic plaques, granuloma annulare and lichen simplex chronicus (neurodermatitis), keloids, discoid lupus erythematosus, necrobiosis lipoidica diabeticorum, alopecia areata